Back to Search
JAE KIM, MD
MD
Urology Physician
NPI: 1225055866IndividualAccepts Medicare
Specialties, Licenses & Credentials
Urology PhysicianPrimary
Urology
Code: 208800000X
036 096031(IL)
CMS Specialties
PrimaryUROLOGY
Education
OTHER
Class of 1992
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
PMID 14707118·J Exp Med·2004
4-observational
Extent of prevalence and size of flat neoplasms in a heterogeneous population undergoing routine colorectal cancer screening.
PMID 19298579·Colorectal Dis·2010
8-other
Assess the effects of culturally relevant intervention on breast cancer knowledge, beliefs, and mammography use among Korean American women.
PMID 19373555·J Immigr Minor Health·2010
8-other
Myeloid-related protein 8/14 levels in children with obstructive sleep apnoea.
PMID 19608587·Eur Respir J·2010
8-other
A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: controlled by ATF3.
PMID 19647793·Cell Signal·2009
7-preclinical
Clinical characteristics of patients with non-specific and non-categorized mitochondrial diseases.
PMID 19659453·Acta Paediatr·2009
8-other
Ducks: the "Trojan horses" of H5N1 influenza.
PMID 19627369·Influenza Other Respir Viruses·2009
6-review
SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin.
PMID 19607816·Biochem Biophys Res Commun·2009
7-preclinical
Voxelized model of interstitial transport in the rat spinal cord following direct infusion into white matter.
PMID 19640132·J Biomech Eng·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 10400 SOUTHWEST HWY
CHICAGO RIDGE, IL 60415 - Phone
- (708) 888-8287
Quick Facts
- NPI
- 1225055866
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 34
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile